LINK Healthcare announced that it has signed an agreement with Sanochemia Pharmazeutika AG for regional rights to Secrelux(R), a pancreatic function diagnostic. LINK has been assigned the exclusive rights to Secrelux(R) for Australia, New Zealand, Japan, South Africa and South East Asia excluding Korea and Philippines.
1st Jan change | Capi. | |
---|---|---|
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B | |
+3.90% | 1.65B |